4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Adicet Bio, Inc. (ACET) operates in the Biotechnology industry and is headquartered in Boston, United States with about 102 employees. Its market capitalization is roughly $73 million. In the fiscal year ended 2025-12-31, ACET reported $0M in revenue and ($117M) in net income.
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $25M |
| Operating Income (EBIT) | ($122M) | ($128M) | ($133M) | ($73M) |
| Net Income | ($117M) | ($117M) | ($143M) | ($70M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($22M) | ($32M) | ($28M) | ($32M) | ($30M) | — |
| Net Income | ($20M) | ($30M) | ($27M) | ($31M) | ($28M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $192M | $220M | $207M | $331M | — |
| Total Liabilities | $33M | $34M | $37M | $38M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ACET viewer.
About TickerBase · Data methodology & sources